Nonalcoholic fatty liver disease (NAFLD), defined as fatty infiltration in > 5% of hepatocytes (steatosis) in the absence of excessive alcohol consumption, is emerging as a leading cause of chronic liver disease worldwide.[1,2] In a subgroup of patients with NAFLD, the disease aggravates to nonalcoholic steatohepatitis (NASH), which in addition to liver lipid accumulation is characterized by local inflammation and hepatocellular damage in the form of ballooning and apoptosis, with different degrees of hepatic fibrosis.[3] NAFLD contributes to the pathogenesis of type 2 diabetes mellitus and cardiovascular disease, and patients with NASH are also at risk of progressing into cirrhosis, liver failure, and hepatocellular carcinoma (HCC).[1,4–6] Despite extensive research being invested in this area of high unmet medical need, the molecular pathogenesis of NAFLD and NASH remains elusive, and no approved drugs are available for their treatment.7]

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Among genetic variants that confer susceptibility to NAFLD/NASH, the best characterized are a single-nucleotide polymorphism (rs738409) in the PNPLA3 (patatin-like phospholipase domain containing 3) gene and a splice variant (rs72613567:TA) in the HSD17B13 gene,[8,9] both of which encode proteins anchored to the intrahepatocellular lipid droplets. Importantly, recent evidence has revealed that the STE20-type kinases comprising the GCKIII subfamily (MST3, MST4, and STK25) also regulate the initiation and aggravation of NAFLD via association with hepatocellular lipid droplets. Together, these data highlight the critical function of liver lipid droplet proteome in NAFLD etiology.

In the following sections, we discuss the newly described roles of GCKIII kinases in the molecular pathogenesis of NAFLD and NASH and explore the underlying mechanisms.

DOMAin STRUCTURE OF THE HUMAN GCKIII SUBFAMILY OF STE20 KINASES

The human kinome features a large branch of STE20 kinases, named after the founding member yeast Sterile20 kinase involved in the mating pathway.[10] Mammalian STE20-type kinases (~30 described to date) are distinguished by a high degree of homology within the catalytic domain, and they fall into two subfamilies: the p21-activated kinases (PAKs) with a C-terminal kinase domain and an N-terminal p21 GTPase-binding domain and the germinal center kinases (GCKs), which have an N-terminal kinase domain and lack GTPase-binding domains.[11] Functionally, STE20 kinases have been reported to regulate a broad range of biological processes including cell differentiation, proliferation, apoptosis, motility, polarity, metastasis, angiogenesis, and stress responses.[12–20]

MST3 (also known as STK24), MST4 (also known as STK26 or MASK), and STK25 (also known as YSK1 or SOK1) comprise the GCKIII subgroup of STE20 proteins. The members of the GCKIII family are ubiquitously expressed and have been implicated in the regulation of Golgi integrity, cytoskeletal organization, cell polarity, proliferation and migration, apoptosis, as well as neuronal and immune functions.[21–27] In humans, MST3 is located on chromosome 13q32.2, whereas MST4 and STK25 are located on Xq26.2 and 2q37.3, respectively.

The kinases in the GCKIII subgroup are the shortest within the STE20 family, with the human proteins ranging from 416 to 431 amino acids in length. At the N-terminal end of GCKIIs, a short variable sequence is followed by a highly conserved domain of 251 residues (about 90% similarity in amino acid sequence).[19,20,25,29] This catalytic domain encompasses the adenosine triphosphate–binding (ATP) site (GXGK) and a protein substrate binding site, which also contains the STE20 signature peptide (GTPFWMAPE) (Figure 1).[12,20] Molecular modeling and crystallographic studies have revealed that the GCKIII catalytic domains
display a typical structure of protein kinase domains, with a smaller N-lobe and a larger C-lobe, and the substrate-binding cleft placed between them. Notably, the lysine residue (Lys$^{19}$ in STK25 and Lys$^{33}$ in MST3/MST4) and the threonine residue (Thr$^{174}$ in STK25 and Thr$^{178}$ in MST3/MST4) within the kinase domain have been identified as instrumental for the catalytic activity of GCKII kinases. Rather than requiring activation by upstream kinase(s), GCKIIIs appear to be activated by constitutive autophosphorylation of Thr$^{174/178}$, suggesting that the primary regulation of MST3, MST4, and STK25 activity lies at the level of inhibition of the Thr$^{174/178}$ dephosphorylation by protein phosphatase(s).

The regulatory domain of MST3, MST4, and STK25 lies at the C-terminal to the catalytic domain and carries a putative bipartite nuclear localization signal at its N-terminal end, which is relatively well conserved (Figure 1). This sequence is followed by a variable region of 119–134 residues (about 20% similarity in amino acid sequence), which is predicted to be highly disordered and is suggested to interact with various signaling molecules and regulatory proteins. As an example, the regulatory domain of all three GCKIIIs has been shown to heterodimerize with PDCCD10 (programmed cell death 10, also known as CCM3). The regulatory region of GCKIIIs also interacts with GOLGA2 (Golgin subfamily A member 2, also known as GM130) in the control of Golgi assembly.

Furthermore, through both regulatory and catalytic domains, GCKIIIs associate with MO25 protein in the LKB1/STRAD/MO25 complex. The regulatory regions appear to be involved in homodimerization of GCKIII kinases, although the exact residues engaged in these interactions are not clearly determined.

Notably, several caspase cleavage sites are predicted in silico within the regulatory domain of MST3, MST4, and STK25, some of which have been experimentally verified. In contrast, MST4 and STK25 have been shown to localize to the Golgi apparatus in the human cervical carcinoma cell line (HeLa) and human embryonic kidney cell line (HEK293), where they function in a signaling cascade required for cell migration and polarization. MST3 has been reported to localize predominantly to the cytosol in HeLa and HEK293 cells; however, following caspase cleavage, the protein translocates to the nucleus inducing apoptosis. Similarly, a cleaved form of STK25 can translocate from the Golgi to the nucleus in HEK293 cells after chemical anoxia, promoting cell death.

Together, these observations suggest that GCKIII kinases display a different subcellular localization pattern in the liver compared with extrahepatic tissues. Furthermore, it is important to investigate whether the localization of GCKIII kinases may change in hepatocytes in response to challenges such as fasting, when very few lipid droplets are present.

**GCKIII KINASES DECORATE INTRAHEPATOCELLULAR LIPID DROPLETS**

Intracellular lipid droplets are composed of a neutral lipid core of primarily triacylglycerol (TAG) and cholesterol esters surrounded by a phospholipid monolayer that harbors specific proteins. By using immunofluorescence microscopy, we found that MST3, MST4, and STK25 are exclusively localized around lipid droplets in human hepatocytes (exemplified by STK25 in Figure 2). Consistently, GCKIII kinases are associated with hepatic lipid droplets in mice, as demonstrated by global proteomic analysis of the lipid droplet fraction isolated from steatotic livers of obese mice as well as using immunofluorescence microscopy of mouse liver sections (Figure 2).

**HEPATIC EXPRESSION OF GCKIII KINASES CORRELATES WITH THE SEVERITY OF HUMAN NAFLD**

We have reported a significant positive correlation between MST3, MST4, and STK25 transcript abundance in human liver biopsies and all three individual lesions of the NAFLD Activity Score (NAS) used for clinical diagnosis (i.e., histological scores of hepatic steatosis, lobular inflammation, and hepatocellular ballooning) as well as total NAS ($n = 62$; Figure 3A–D). Moreover, messenger RNA (mRNA) levels of MST3, MST4, and STK25 were about 2–3-fold higher in subjects with NAS $\geq 5$ (defines definite NASH; $n = 24$) compared to participants.
with NAS ≤ 4 (defines simple steatosis or borderline NASH; n = 38) (Figure 3E). We also found a positive correlation between the hepatic expression of GCKIII kinases and the liver fat content assessed by magnetic resonance spectroscopy (Figure 3F).

GCKIII KINASES CELL-AUTONOMOUSLY CONTROL LIPID STORAGE AND METABOLIC STRESS IN HUMAN HEPATOCYTES

Our recent studies reveal that small interfering RNA silencing of MST3, MST4, or STK25 in human hepatocytes markedly reduces intracellular lipid accumulation, which is mediated by increased β-oxidation and very low-density lipoprotein (VLDL)–TAG secretion (i.e., output), combined with decreased TAG synthesis (i.e., input) (Figure 4). Importantly, MST3-, MST4-, or STK25-deficient hepatocytes are also substantially protected against oxidative and endoplasmic reticulum (ER) stress which are considered the key triggers of disease progression from simple liver steatosis to NASH. Reciprocally, a substantial increase in lipid deposition as well as oxidative/ER stress was detected in human hepatocytes overexpressing GCKIII kinases. With these data describing the functional implications of modified MST3, MST4, and STK25 abundance on lipid partitioning and metabolic stress being highly consistent, the underlying mechanisms of GCKIII signaling in the regulation of intrahepatocellular lipid homeostasis still remain elusive. Further unbiased investigations combining global phosphoproteomics, interactomics, and substrate mapping would be valuable to identify the interaction partners and direct targets of GCKIII kinases to decipher their molecular mode-of-action in hepatic lipid metabolism. It would
also be interesting to use advanced imaging (e.g., superresolution microscopy or correlative light-electron microscopy) to examine whether GCKIII kinases affect the interactions of liver lipid droplets with other cellular organelles including ER, mitochondria, peroxisomes, and lysosomes.

The possible role of MST3, MST4, and STK25 in glucose metabolism has not been studied in detail in hepatocytes. However, in vivo data support the impact of GCKIII kinases on the control of glucose and insulin homeostasis (see subsequent section). Of note, STK25 was shown to negatively regulate the aerobic glycolysis in colorectal cancer cells via mammalian target of rapamycin (mTOR) signaling. [79]

SILENCING OF STK25 OR MST3 HINDERS THE DEVELOPMENT OF NASH IN MICE

The main pathophysiological characteristics of human NALFD can be replicated in rodent models by different dietary challenges. We found that, when challenged with a NASH-inducing diet, the livers from Stk25 knockout mice and mice treated with Stk25-targeting antisense oligonucleotides (ASOs) display substantial suppression of integral NASH features compared with wild-type livers: Along with less steatosis, we observed attenuation of oxidative stress, inflammation, and fibrosis, combined with reduced hepatocellular damage (Figure 5). [80–82] This improvement of the liver phenotype correlates with a decrease in the hepatic levels of acetyl-CoA carboxylase (ACC) protein, a key regulator of both lipid oxidation and synthesis. [80–82] Reciprocally, we show that diet-induced NASH is markedly aggravated in Stk25-overexpressing transgenic versus wild-type mice. [74,75] Of note, high-fat–fed Stk25+/− mice also accumulate less ectopic fat in extrahepatic tissues such as skeletal muscle, kidney, and vascular wall, and have healthier adipose tissue, [82–85] which is accompanied by improved whole-body glucose tolerance and insulin sensitivity [82] compared with wild-type littermates.

Similarly to the silencing of STK25, we found that mice treated with Mst3-targeting ASOs are significantly protected against diet-induced NASH, which is also paralleled by a lower abundance of liver ACC. [86] In light of the recent evidence of an association and causal link between NASH and insulin resistance, [5,87] our results are in line with a study by Iglesias et al. reporting that Mst3 genetrap mice (which have a significant but not complete reduction of Mst3 expression) fed with a high-fat diet display improved hepatic insulin sensitivity compared with wild-type controls. [88] In the livers from high fat–fed mice, the loss of MST3 was also shown to increase the signaling of the insulin receptor pathway at the level of AKT phosphorylation, accompanied by high activity of mTOR complex 2. [88] In contrast, Qin et al. found that elimination of MST3 in mice promoted high-fat diet–induced systemic glucose intolerance and insulin resistance, and attenuated phosphorylation of AKT in adipose tissue and liver. [89] It is possible that the differences in the genetic background of mouse strains studied, and composition of the high-fat diets used, have contributed to this variability in results.

To date, there are no studies in nonclinical in vivo models that implicate MST4 in the development of NAFLD/NASH. However, there is some indirect evidence suggesting that MST4 may regulate liver fibrosis [90] and MST4 has also been described as a critical mediator limiting inflammatory responses in extrahepatic tissues. [23,91]

ROLE OF GCKIII KINASES IN HCC

Recently, NASH has been reported in several studies as a rapidly increasing underlying etiology of HCC. [92–94] which is one of the most fatal and fastest-growing cancers. [95] Interestingly, we found that the genetic ablation of STK25 protects mice against NASH-driven HCC via

![Figure 4](image-url)
reduced hepatocellular apoptosis and lowered compensatory proliferation, by a mechanism that involves the suppression of hepatic lipotoxicity and inactivation of liver signal transducer and activator of transcription 3 (STAT3), extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 signaling—the key pathways implicated in human HCC (Figure 5). In line with these observations, short hairpin RNA knockdown of STK25 has been demonstrated to inhibit tumor growth in human HCC xenografts in nude mice. The silencing of STK25 also suppresses proliferation, migration, and invasion in human hepatocarcinoma cells in vitro, which is accompanied by a lower expression of the markers of epithelial–mesenchymal transition (EMT) and augmented autophagic flux. Furthermore, high STK25 expression was found to be correlated with adverse clinicopathological characteristics and poor survival in patients with HCC.

A report by Lim et al. has described STK25 as an activator of the Hippo pathway in the liver by phosphorylation of LATS. The Hippo signaling is known to maintain tissue homeostasis and organ size by negatively regulating the oncogenic transcriptional co-activators yes-associated protein 1 (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ). Consistently, STK25 knockdown was reported to result in a moderate increase in liver weight in aged mice; however, hepatic carcinomas were not detected.

In contrary, a recent study by Bae et al. has identified STK25 as a suppressor of the Hippo pathway in human embryonic kidney cells by inhibition of STE20-type kinase MST2. In all, STK25 may display both positive and negative impact on Hippo signaling depending on the downstream targets involved.

Evidence supporting the involvement of MST4 in HCC is contradictory. A high level of liver MST4 expression, associated with large tumor size, microvascular invasion, and presence of intrahepatic metastasis, has been reported as an adverse prognostic factor for overall survival and time to recurrence after hepatectomy in patients with HCC. In the same study, the knockdown of MST4 in human HCC cell lines (MHCC-97H and SMMC7721 cells) was shown to inhibit proliferation, colony formation, and invasion, whereas up-regulation of MST4 appeared to aggravate these processes by promoting EMT via the activation of ERK signaling. Conversely, a low MST4 expression has also been reported to correlate with HCC progression and poor prognosis, and MST4 inactivation was
found to induce EMT in human HCC cell lines (Bel-7402, Bel-7404, and Huh7 cells), promoting their migratory and invasive potential in vitro, and facilitating intrahepatic metastasis in vivo, with the opposite phenotype observed when MST4 is overexpressed. Similarly to STK25, MST4 is suggested to act in the Hippo signaling pathway: MST4 is described as a bona fide kinase of YAP, phosphorylating YAP at Thr83 and causing an impaired nuclear importing of YAP.

MST3 has also been implicated in the Hippo pathway: Under certain circumstances, MST3 directly phosphorylates the nuclear Dbf2-related kinase, which in turn phosphorylates and inhibits YAP. The possible role of MST3 in HCC initiation and progression is yet to be explored; however, MST3 has been reported to act both as a positive or negative regulator of tumorigenesis in extrahepatic tissues.

CONCLUSIONS
Recent translational studies in patient cohorts, cultured human cells, and mouse models provide several lines of experimental evidence suggesting that GCKIII kinases MST3, MST4, and STK25 are important components of the hepatocellular lipotoxic milieu. Antagonizing hepatic GCKIII signaling appears to enable targeting of the initiating nexus for lipid-triggered liver injury in NAFLD, warranting further investigations in basic biology as well as clinical implications of these kinases.

FUNDING INFORMATION
Supported by a grant from the Swedish Research Council.

CONFLICT OF INTEREST
Nothing to report.

REFERENCES
1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–24.
2. Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut. 2021;70:1570–9.
3. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–83.
4. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411–28.
5. Tang J, Ip JP, Ye T, Ng YP, Yung WH, Wu Z, et al. Cdk5-dependent MST3 phosphorylation and activity regulate neuronal migration through RhoA inhibition. J Neurosci. 2014;34:7425–36.
6. Sugden PH, McGuffin LJ, Clerk A. SOcK, MiSTs, MASK and STIckks: the GCKIII (germlinal centre kinase III) kinases and their heterologous protein-protein interactions. Biochem J. 2013;454:13–30.
7. Pombo CM, Iglesias C, Sartages M, Balvize JB. MST Kinases and Metabolism. Endocrinology. 2019;160:1111–8.
8. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096–106.
9. Mango S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.
10. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.
11. Strange K, Denton J, Nehrke K. Ste20-type kinases: evolutionarily conserved regulators of ion transport and cell volume. Physiology (Bethesda). 2008;25:1–8.
12. Dan I, Watanabe NM, Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol. 2011;11:220–30.
13. Zhao ZS, Manser E. PAK family kinases: physiological roles and regulation. Cell. 2012;15:259–68.
14. Wu A, Jiang X. p21-Activated kinases as promising therapeutic targets in hematological malignancies. Leukemia. 2021;36:315–26.
15. Kumar R, Sanawar R, Li X, Li F. Structure, biochemistry, and biology of PAK kinases. Gene. 2017;605:20–31.
16. Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14:13–25.
17. Ye DZ, Field J. PAK signaling in cancer. Cell. 2012;2:105–16.
18. Whale A, Hashim FN, Fram S, Jones GE, Wells CM. Signalling to cancer cell invasion through PAK family kinases. Front Biosci (Landmark Ed). 2011;16:849–64.
19. Delpire E. The mammalian family of sterile 20p-like protein kinases. Pflugers Arch. 2009;458:953–67.
20. Ling P, Lu TJ, Yuan CJ, Lai MD. Biosignaling of mammalian Ste20-related kinases. Cell Signal. 2008;20:1237–47.
21. Ulatar SK, Yadav S, Hertz NT, Oses-Prieto JA, Claxton S, Burlingame AL, et al. MST3 kinase phosphorylates TAO1/2 to enable Myosin Va function in promoting spine synapse development. Neurosci. 2014;84:968–82.
22. Matsuki T, Matthews RT, Cooper JA, van der Brug MP, Cookson MR, Hardy JA, et al. Reelin and stk25 have opposing roles in neuronal polarization and dendritic Golgi deployment. Cell. 2010;143:826–36.
23. Jiao S, Zhang Z, Li C, Huang M, Shi Z, Wang Y, et al. The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6. Nat Immunol. 2015;16:246–57.
24. Tang J, Ip JP, Ye T, Ng YP, Yung WH, Wu Z, et al. Cdk5-dependent MST3 phosphorylation and activity regulate neuronal migration through RhoA inhibition. J Neurosci. 2014;34:7425–36.
25. Sugden PH, McGuffin LJ, Clerk A. SOcK, MiSTs, MASK and STIckks: the GCKIII (germlinal centre kinase III) kinases and their heterologous protein-protein interactions. Biochem J. 2013;454:13–30.
26. Pombo CM, Force T, Kyriakos J, Nogueira E, Fidalgo M, Balvize J. The GCK II and III subfamilies of the STE20 group kinases. Front Biosci. 2007;12:850–9.
GCKIII Kinases in Hepatic Lipotoxicity

31. Ko TP, Jeng WY, Liu CI, Lai MD, Wu CL, Chang WJ, et al. Structures of human MST3 kinase in complex with adenine, ADP and Mn2+. Acta Crystallogr D Biol Crystallogr. 2010;66:145–54.

32. Record CJ, Chaikuad A, Rellos P, Das S, Pike AC, Fedorov O, et al. Structural comparison of human mammalian ste20-like kinases. PLoS One. 2010;5:e11905.

33. Fuller SJ, McGuffin LJ, Marshall AK, Giraldo A, Pikkarainen S, Hao Q, Feng M, Shi ZB, Li CC, Chen M, Wang WJ, Huang CY, Wu YM, Hsu CY, Lee WS, Lai MD, Lu TJ, Jiang H, Wang WW, Zhang Y, Yao WW, Jiang JY, Qin B, et al. Structural insights into regulatory mechanisms of MO25-mediated kinase activation. J Str Biol. 2014;186:224–33.

34. Shi Z, Jiao S, Zhang Z, Ma M, Zhang Z, Chen C, et al. Structure of the MST4 in complex with MO25 provides insights into its activation mechanism. Structure. 2013;21:449–61.

35. Hao Q, Feng M, Shi ZB, Li CC, Chen M, Wang WJ, et al. Structural insights into regulatory mechanisms of MO25-mediated kinase activation. J Str Biol. 2014;186:224–33.

36. Voss K, Stahl S, Schleider E, Ullrich S, Nickel J, Mueller TD, Voss K, Stahl S, Hogan BM, Reinders J, Schleider E, Schulte-Berndt A, et al. PP2A phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics. 2011;120:2795–804.

37. Goudreault M, D’Ambrosio LM, Kean MJ, Mullin MJ, Larsen BG, Sanchez A, et al. A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics. 2011;10:2795–804.

38. Schinkmann K, Blenis J. Cloning and characterization of a Ste20 and SPS1, but is not involved in the known MAPK pathways. Oncogene. 1997;14:2047–57.

39. Lin CY, Wu HY, Wang PL, Yuan CJ. Mammalian Ste20-like kinase to orchestrate histamine-stimulated acid secretion in gastric parietal cells. J Biol Chem. 2015;290:28272–85.

40. Lu TJ, Lai WY, Huang CY, Hsieh WJ, Yu JS, Hsieh YJ, et al. Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (Mst3). Nuclear translocation and induction of apoptosis. J Biol Chem. 2002;277:34367–74.

41. Schinkmann K, Blenis J. Cloning and characterization of a Ste20 and SPS1, but is not involved in the known MAPK pathways. Oncogene. 1997;14:2047–57.

42. Shirasaka S, Hirai S, et al. SOK1 translocates from the Golgi to the nucleus upon activation mechanism. Structure. 2013;21:449–61.

43. Osada S, Izawa M, Saito R, Mizuno K, Suzuki A, Hirai S, et al. Nuclear translocation and induction of apoptosis. J Biol Chem. 2002;277:34367–74.

44. Thiriet M. Intracellular Signaling Mediators in the Circulatory and Ventilatory Systems. Berlin, Germany: Springer Science & Business Media; 2012.

45. Thiriet M. Intracellular Signaling Mediators in the Circulatory and Ventilatory Systems. Berlin, Germany: Springer Science & Business Media; 2012.

46. Ceccarelli DF, Laister RC, Mulligan VK, Kean MJ, Goudreault M, Scott IC, et al. CCM3/PDCD10 heterodimerizes with germinal center kinase III (GCKIII) proteins using a mechanism analogous to CCM3 homodimerization. J Biol Chem. 2011;286:25056–64.

47. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005;437:1173–8.

48. Ma X, Zhao H, Shan J, Long F, Chen Y, Chen Y, et al. PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway. Mol Biol Cell. 2007;18:1965–78.

49. Voss K, Stahl S, Schieder E, Ullrich S, Nickel J, Mueller TD, et al. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics. 2007;8:249–56.

50. Fidalgo M, Fraile M, Pires A, Force T, Pombo C, Zalvide J. CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. J Cell Sci. 2010;123:1274–84.
68. Mashek DG. Hepatic lipid droplets: a balancing act between energy storage and metabolic dysfunction in NAFLD. Mol Metab. 2021;50:101115.

69. Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Bio. 2019;20:137–55.

70. Amrutkar M, Kern M, Nunez-Duran E, Stahlman M, Lansby E, Chursa U, et al. Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans. Diabetologia. 2016;59:341–53.

71. Cansby E, Kulkarni NM, Magnunsson E, Kurhe Y, Amrutkar M, Nerstedt A, et al. Protein kinase MST3 regulates hepatic steatohepatitis in humans. FASEB J. 2019;33:9974–89.

72. Caputo M, Cansby E, Kumari S, Kurhe Y, Nair S, Stahlman M, et al. STE20-type protein kinase MST4 controls NAFLD progression by regulating lipid droplet dynamics and metabolic stress in hepatocytes. Hepatol Commun. 2021;5:1183–200.

73. Nerstedt A, Kurhe Y, Lansby E, Caputo M, Gao L, Vorontsov E, et al. Lipid droplet-associate kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver. J Lipid Res. 2020;61:178–91.

74. Amrutkar M, Cansby E, Nunez-Duran E, Pirazzi C, Stahlman M, Sutt S, et al. STK25 is a critical determinant in nonalcoholic steatohepatitis. FASEB J. 2016;30:3628–43.

75. Amrutkar M, Chursa U, Kern M, Nunez-Duran E, Stahlman M, Sutt S, et al. STK25 is a critical determinant in nonalcoholic steatohepatitis. FASEB J. 2016;30:3628–43.

76. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and progression of liver steatosis and NASH. FASEB J. 2015;29:1564–76.

77. Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21:541–57.

78. Chao HW, Chao SW, Lin H, Ket HC, Cheng CF. Homeostasis of glucose and lipid in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20:298.

79. Qin Q, Shou J, Li M, Gu M, Meng Z, Xu P, et al. Stk24 protects against obesity-associated metabolic disorders by disrupting the NLRP3 inflammasome. Cell Rep. 2021;35:109161.

80. Luo Y, Huo Y, Song P, Zhang X, Liao M. Validation and functional analysis of the critical proteins in combination with tau-rine, epigallocatechin gallate and genistein against liver fibrosis in rats. Biomed Pharmacother. 2019;115:108975.

81. Luan D, Zhang Y, Yuan L, Chu Z, Ma L, Xu Y, et al. MST4 modulates the neuro-inflammatory response by regulating IkappaBalp signaling pathway and affects the early outcome of experimental ischemic stroke in mice. Brain Res Bull. 2020;154:43–50.

82. Dyson J, Jaques B, Chattopadhyay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.

83. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44.

84. Sanayal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183–91.

85. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

86. Kurhe Y, Lansby E, Cansby E, Xia Y, Kumari S, Anand SK, et al. Antagonizing STK25 signaling suppresses the development of hepatocellular carcinoma through targeting metabolic, inflammatory, and pro-angiogenic pathways. Cell Mol Gastroenterol Hepatol. 2022;13:405–23.

87. Zhang Y, Xu J, Qiu Z, Guan Y, Zhang X, Zhang X, et al. STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway. Cancer Cell Int. 2022;22:4.

88. Lim S, Hermance N, Mundtano T, Mustaly HM, Mauricio IPM, Vitoria MA, et al. Identification of the kinase STK25 as an upstream activator of LATS signaling. Nat Commun. 2019;10:1547.

89. Russell JO, Camargo FD. Hippo signaling in the liver: role in development, regeneration and disease. Nat Rev Gastroenterol Hepatol. 2022;19:297–312.

90. Bae SJ, Ni L, Luo X. STK25 suppresses Hippo signaling by regulating SAV1-STRIPAK antagonism. Elife. 2020;9:e54863.

91. Lin ZH, Wang L, Zhang JB, Liu Y, Li XQ, Guan J, et al. MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway. Int J Oncol. 2014;45:629–40.

92. Dian MJ, Li J, Zhang XL, Li ZJ, Zhou Y, Zhou W, et al. MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis. J Cancer. 2021;12:4463–77.

93. Hao WC, Zhou L, Zhang Q, Lin H, Li XQ, Guo L, et al. MST4 promotes hepatocellular carcinoma through targeting metabolic, inflammatory, and pro-angiogenic pathways. J Mol Gastroenterol Hepatol. 2022;13:405–23.

94. Amrutkar M, Cansby E, Chursa U, Nunez-Duran E, Chanclon B, Stahlman M, et al. Genetic disruption of protein kinase STK25 ameliorates metabolic defects in a diet-induced type 2 diabetes model. Diabetes. 2015;64:2791–804.

95. Cansby E, Lansby E, Nunez-Duran E, Serine/threonine kinase 25 antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. FASEB J. 2021;35:e21567.
the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer. J Biol Chem. 2018;293:14455–69.

106. Stegert MR, Hergovich A, Tamaskovic R, Bichsel SJ, Hemmings BA. Regulation of NDR protein kinase by hydrophobic motif phosphorylation mediated by the mammalian Ste20-like kinase MST3. Mol Cell Biol. 2005;25:11019–29.

107. Rausch V, Hansen CG. The hippo pathway, YAP/TAZ, and the plasma membrane. Trends Cell Biol. 2020;30:32–48.

108. Chen YL, Wang CY, Fang JH, Hsu HP. Serine/threonine-protein kinase 24 is an inhibitor of gastric cancer metastasis through suppressing CDH1 gene and enhancing stemness. Am J Cancer Res. 2021;11:4277–93.

109. Lee KT, Chang CL, Li CY, Song H, Shan YS, Lai MD. The oncogenic role of MST3 in human gastric cancer. Am J Cancer Res. 2018;8:2130–9.

110. Madsen CD, Hooper S, Tozluoglu M, Bruckbauer A, Fletcher G, Erler JT, et al. STRIPAK components determine mode of cancer cell migration and metastasis. Nat Cell Biol. 2015;17:68–80.

How to cite this article: Mahlapuu M, Caputo M, Xia Y, Cansby E. GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond. Hepatol Commun. 2022;6:2613–2622. https://doi.org/10.1002/hep4.2013